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Abstract
The novel coronavirus SARS-CoV-2 and resulting COVID-19 infection has spread from a
cluster of unidentified pneumonia cases in Wuhan, China, into an ongoing global health crisis.
The strain on the healthcare systems and loss of human life has made finding ways to treat severe
COVID-19 infections of the utmost importance. Mortality from COVID-19 has been shown to
result from an overwhelming inflammatory response similar to the cytokine release syndrome
seen in certain autoimmune reactions (Tleyjeh et al., 2020). It also can be seen after chimeric
antigen receptor T-cell (CAR-T) therapy for certain cancers. It is hypothesized that treatments
targeting the prevention of the “cytokine storm” would improve patient outcomes. One of the
specific intended targets is that of interleukin 6 (IL-6), one of the pro-inflammatory cytokines
found in the cytokine release syndrome (CRS). Tocilizumab is a medication that is potentially
given post CAR-T therapy to prevent CRS (Campochiaro et al., 2020) This medication works by
inhibiting IL-6 and halting the immune response that triggers the inflammatory cascade. This
review of the literature examines the efficacy of tocilizumab in the treatment of severe COVID19 infections.
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Introduction
Introduction to the Inquiry
The novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was
first identified at the end of 2019 following an outbreak of unexplained pneumonia cases in
Wuhan, China (Alzghari & Acuna, 2020). The resulting infection, officially labeled the
coronavirus disease 2019 (COVID-19) on February 11, 2020, has since spread into a global
pandemic and a public health crisis (Xu et al., 2020). As of November 24, 2021, COVID-19 has
been identified in 259 million cases and 5.17 million deaths worldwide and is still causing
turmoil throughout the globe (Centers for Disease Control and Prevention, [CDC], 2021) The
United States has had 47.8 million cases and 772,180 deaths thus far, and the numbers continue
to climb (CDC, 2021). Treatment for COVID-19 is supportive in nature and aims to shorten
disease course and diminish disease severity. Therefore, the research regarding these potential
therapies is of paramount importance.
SARS-CoV-2 is a ribonucleic acid (RNA) virus from the genus Betacoronavirus that
utilizes a glycoprotein, or spike protein, to bind to the host’s angiotensin-converting enzyme 2
(ACE2) receptor (Stasi et al., 2020). Once the spike protein is bound to the ACE2 receptor, the
virus gains entry to the host cell via the protease TGRBSS2 (Stasi et al., 2020).
COVID-19 has extremely variable clinical course from person to person. In some cases,
it is asymptomatic while others become critically ill and develop acute respiratory distress
syndrome (ARDS) (Salveti et al., 2020). Individuals with altered immune function and the
elderly are particularly susceptible to severe disease and have higher mortality rates (Xu et al,
2020). Individual susceptibility of the host to potentiating a dysfunctional immune response
seems to be associated with increased severity of the disease process (Menzella et al., 2020). Lan
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et al. (2020) found that severe cases of COVID-19 have an overall mortality rate of 6.36%,
although multiple variants have different outcomes and mortality rates differ greatly across age
groups.
Background and Reason for Inquiry
Individuals with a severe clinical course requiring intensive care treatment often present
in a hyperinflammatory state. The lab values of these critically ill patients show elevated serum
interleukin-6 (IL-6) levels and other pro-inflammatory cytokines, which represent a “cytokine
storm” or cytokine release syndrome (CRS) (Lan et al., 2020). Dastan et al. (2020) used an IL-6
level over 10 pg/mL as a marker of hyperinflammation. Elevated tumor necrosis factor and
granulocyte colony stimulating factor were also noted (Mady et al., 2020). CRS seems to play a
role in severe COVID-19 (Klopfenstein, et al. 2020).
Mady et al. (2020) found that the increase in inflammatory factors can cause a myriad of
clinical problems that worsen the disease course. Post-mortem examination of COVID-19 lung
tissue found micro thrombosis, proteinaceous exudate, and alveolar edema, which suggests that
the hyperinflammation and associated thromboembolic disease enhanced the lung tissue damage
and resulting fibrosis (Mady, et al, 2020). Other laboratory values such as an elevated C-reactive
protein (CRP), ferritin, and D-Dimer were also noted and further represent a dysregulation of the
immune system (Mady et al., 2020). Campochiaro et al. (2020) defined hyperinflammation as
having a CRP greater than or equal to 100 mg/L and a ferritin of greater than or equal to 900
ng/mL. Klopfenstein et al. (2020) reported that elevations in CRP, ferritin, and IL-6 to represent
a significant increase in mortality for this patient population.
CRS is associated with many of the negative clinical outcomes seen in COVID-19 and
may contribute to an elevated morbidity and mortality (Price et al., 2020). In CRS, the release of
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pro-inflammatory cytokines occurs in response to the activation of the immune system’s
inflammatory cascade. The resulting inflammation is associated with cardiovascular events,
multi-organ failure, and death (Price et al., 2020). Klopfenstein et al (2020) also attributes the
lung injury titled acute respiratory distress syndrome (ARDS) seen in COVID-19 to this cytokine
inflammatory response. The post-viral hyperinflammation usually occurs in the second week of
the illness and is associated with worsening severity of the disease (Klopfenstein et al, 2020).
When the immune system is acting properly, macrophages are activated via two methods,
damage-associated molecular patterns (DAMPS), and pathogen-associated molecular patterns
(PAMPS). DAMPS are pieces of cells damaged by the virus. PAMPS are part of the virus
themselves, such as viral RNA (Tleyjeh et al., 2020). These molecules activate receptors which
then trigger an innate antiviral immune response and adaptive immunity to fight the infection and
begin the healing process.
Severe COVID-19 disease seems to be caused by the dysregulation of this innate immune
response, most likely activated by a type of cell death called pyroptosis. Pyroptosis activates
several proinflammatory cytokines (including IL-6) that promote immune recruitment to the
affected tissues. This immune overreaction promotes an increase of cell damage (Tleyjeh et al.,
2020).
The elevation of these cytokines and other proinflammatory markers are associated with
higher disease severity and worsening overall prognosis in COVID-19 infection (Tleyjeh et al.,
2020). Therefore, treatments aiming to reduce this immune reaction and decreasing the levels of
proinflammatory markers are now being evaluated.
There are various antiviral and immunomodulatory agents being used to attempt to
improve patient outcomes, and research is ongoing. One of the therapeutic options being studied
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is the use of tocilizumab to blunt the uncontrolled immune reaction and cytokine storm seen in
severe COVID-19 infections.
Tocilizumab (TCZ) is being used to attempt to reduce morbidity and mortality in severe
to critically ill patients with COVID-19 (Malekzadeh et al., 2020). TCZ is currently approved for
use in the treatment of rheumatoid arthritis, giant cell arteritis, and juvenile idiopathic arthritis. It
is also one of the approved therapeutics in use to treat CRS, a life-threatening complication noted
following chimeric antigen receptor T-cell therapy (CAR T-cell therapy) for certain cancers
(Campochiaro et al., 2020).
Individuals who present with severe and critical COVID-19 disease have clinical and
laboratory signs that are also seen in CRS. They often have high fevers, severe muscle pain and
fatigue. Their labs show elevated inflammatory markers such as C-reactive protein, ferritin
levels, and IL-6. Due to these similarities, TCZ was approved in many countries for off-label use
in the setting of the global pandemic to attempt to slow or curtail progression of the disease
course (Campochiaro et al., 2020).
TCZ is a recombinant humanized monoclonal antibody that works as an IL-6 receptor
antagonist (Lan et al., 2020). The goal for the TCZ therapy in the setting of COVID-19 is to
block the pro-inflammatory activity that leads to multi-organ failure in this patient population.
Pneumonia and the subsequent respiratory failure is the most common cause of death in patients
with COVID-19 infections (Perrone et al., 2020). By neutralizing the IL-6 inflammatory factor in
the cytokine release syndrome, the aim is to then block the resulting cytokine storm and diminish
the severity of disease (Klopfenstein et al., 2020).
Purpose of the Inquiry
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Investigating the efficacy of possible COVID-19 therapeutics is of utmost importance, as
the COVID-19 pandemic continues to have a profound impact on society and the healthcare
system. The purpose of this scholarly inquiry is to examine the literature describing the use of
TCZ in the treatment of severe to critical COVID-19 infections. The rationale for the inquiry is
to identify best-practice TCZ treatment for this patient population, as the science surrounding
this novel infection is evolving.
Clinical Question
Based on the above information, a clinical question was created to guide the literature
search and resulting literature review. The clinical question, in the PICO format where (P) is
Population, (I) is the Intervention, (C) is the Control, and (O) is the Outcome is as follows: for
patients with severe to critical COVID-19 infections, does the administration of TCZ compared
with standard treatment have a positive impact on patient outcomes? Outcomes for the sake of
this inquiry would be limited to reduced morbidity, mortality, or other clinical improvements
such as the level of oxygen support.
Inquiry Method
The method used for this scholarly inquiry paper was an integrative literature review.
This method of inquiry provides an extensive review of the of the evidence in the literature with
the aim of further understanding the clinical problem and evaluating the possible intervention.
The literature is then assessed to provide insight and recommendations regarding the clinical
problem described above.
Literature Review
Introduction
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A literature review was conducted using several search engines to evaluate the use of
TCZ in the treatment of severe COVID-19 infection and to review the current studies available
on the emerging topic. The articles that were selected for this review were chosen based on their
level of evidence. The level of evidence was rated according to Ackley, Swan, Ladwig, and
Tucker (2008). Several themes from the literature were identified. The available evidence was
evaluated, and recommendations made for the clinical problem based on these findings.
Search Strategy
Multiple search engines were used to conduct the extensive literature search on the topic
(see Table 1). The initial search engines included were: CINAHL, PubMed, and Science Direct.
Keywords to help guide the initial investigation included: COVID-19, coronavirus, and
monoclonal, and outcomes. To further narrow the search, the keywords of tocilizumab,
treatment, and COVID were also searched together.
The initial search was conducted on two dates in December of 2020 and January of 2021.
The articles chosen for this inquiry were all current, as COVID-19 is an emerging disease. All
studies used in this inquiry were published in 2020. The articles chosen based on abstracts that
evaluated the use of TCZ in the treatment of severe coronavirus. Excluded articles included
studies using other monoclonal antibody treatments or those that had very low-level evidence
such as case studies. The chosen studies for this integrative literature review can be viewed in
Table 2. The articles that were selected range in level of evidence from systematic review to
retrospective cohort studies.
Levels of Evidence
Each chosen article was evaluated via the evidence framework designed by Ackley, et al.
(2008) and are listed for review in Table 3. The assigned levels of evidence are as follows: two
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systematic reviews and meta-analyses (Level I evidence), seven controlled trials without
randomization (Level III evidence), and six case-control or cohort studies (Level IV evidence).
High-level research was difficult to find, as the pandemic is still evolving and lower-level case
study articles were generally excluded.
Appraisal and Themes
A review of the chosen articles was conducted, investigating the safety and efficacy of
TCZ as a possible treatment of severe COVID-19 infections. Various themes emerged from the
literature review and are summarized in Table 4. These included: CRS/cytokine storm, the route
of administration, concurrent steroid use, treatment safety, and varying recommendations for use.
CRS/Cytokine Storm
The most consistent theme found within the literature was regarding the
hyperinflammatory response found in severe COVID-19 infections, and how targeted prevention
or treatment of this response is a possible key to improving patient outcomes. This theme was
mentioned in some form in all fifteen chosen articles.
Clinical severity in COVID-19 infection appears to be related to the cytokine storm
brought on by the overproduction of inflammatory mediators and seems to be associated with
higher mortality (Rossotti, et al., 2020). Patients hospitalized with severe COVID-19 disease
have elevated laboratory values of inflammatory cytokines, especially interleukin 6 (IL-6)
(Alzghari & Acuna, 2020). Dastan, et al., (2020) attributes the pathophysiology of COVID-19 to
this hyperinflammatory response, or CRS.
The inflammatory cascade, activated by the body in response to the pathogen, leads to the
severe multi-organ failure and resulting complications that leads to death in this patient
population. Due to this cascade effect, early recognition and treatment of CRS is of utmost
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importance (Dastan, et al., 2020). Klopfenstein et al. (2020) identified elevated inflammatory
markers such as ferritin, CRP, and IL-6 as associated with increased mortality and that
neutralizing CRS markers could potentially reduce disease severity.
Lan et al. (2020) stated that while many different markers were part of the CRS
inflammatory cascade, IL-6 was deemed the most important, and that blocking IL-6 may inhibit
the cascade. Mady et al. echoes the importance of IL-6, calling it a “pivotal inflammatory
mediator in the development of COVID-19 associated hyperinflammation” (2020, p. 418).
Elevated CRP, D-dimer, ferritin, and lactate dehydrogenase were also noted as markers found in
those patients with evolving respiratory collapse (Mady et al., 2020).
The pathogenesis of COVID-19 can vary greatly. In mild or asymptomatic cases, the
immune response by the infected individual is controlled and effective at reducing viral load
(Malekzadeh et al., 2020). This is lost, however, if the virus can evade and trigger a dysregulated
immune response by the host, setting off the cascade and mass release of inflammatory
cytokines. The combined response of direct destruction of infected cells and the secondary
damage done by the hyperinflammatory immune response together leads to respiratory damage
and resulting poor clinical response (Malekzadeh et al., 2020).
Menzella et al. (2020) also discusses the variability of clinical severity seen in COVID19. Factors such as viral load, patient comorbidities, and individual susceptibility are noted to
impact and moderate the body’s response, and the cytokine storm is attributed to the evolution of
some cases to organ failure and death (Menzella et al., 2020). Menzella et al. (2020) also
observed that higher IL-6 levels were found in the more complicated disease states then those
with paucisymptomatic cases.
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Perrone et al. (2020) associates the excessive immune response by the host as the cause
of COVID-19 pneumonia and evolving ARDS. IL-6 is also identified as the instigating factor in
CRS as well as other rheumatic diseases, such as rheumatoid arthritis (Perrone et al., 2020). In
contrast, Price et al. (2020) marks CRS by elevations in CRP versus IL-6. The article then states
that elevated IL-6 seems to have an important contribution to the CRS seen in COVID-19, and
that blocking the IL-6 pathway may decrease disease severity (Price et al., 2020).
Salvati et al. (2020) highlights the similarities of the cytokine storm seen in severe
COVID-19 infections with those seen in CAR T-cell-induced CRS, an adverse reaction
following CAR T-cell infusion for certain cancers. Tocilizumab has been approved for the
treatment of CAR T-cell CRS since 2017, explaining why it may have a potential benefit for the
hyperinflammatory CRS in COVID-19 (Salvati et al., 2020).
The overactive immune response may be activated by pyroptosis, a type of cell death that
initiates a chain reaction utilizing several inflammatory cytokines and chemokines, including IL6. IL-6, along with other cytokines, recruit cytotoxic T cells and neutrophils to affected tissues
and the resulting inflammation causes the multiorgan damage seen in severe COVID-19 (Tleyjeh
et al., 2020). This delayed, overactive immune response and cytokine storm is also seen in other
respiratory diseases, such as severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS). The elevated inflammatory markers seen in these syndromes are
like those seen in severe COVID-19, implying that CRS plays a role in the pathogenesis of
COVID-19 as well (Xu et al., 2020).
TCZ, a humanized monoclonal antibody used to combat CRS secondary to other
diseases, may also be an effective treatment for COVID 19, as targeting the IL-6 receptors may
interrupt the inflammatory cascade and improve patient outcomes (Tleyjeh et al., 2020). Zhao,
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Cui, and Tian (2020) hypothesized that IL-6 binding to the IL-6 receptor may transmit
inflammatory signals as well as activate other signal pathways, contributing to ARDS and poor
patient outcomes. The article states that blocking the IL-6 pathway may be a way to avoid the
organ dysfunction associated with the inflammatory cascade, explaining why TCZ was worth
further study (Zhao, et al., 2020). Campochiaro et al., echoes that “timely inhibition of
inflammation with tocilizumab could be clinically effective for this population” (2020, p. 44).
The level of evidence to support the reduction of CRS as a therapeutic target is welldocumented. Nearly every article found in the literature review discusses the inflammatory
process and that curtailing this cascade would have clinical benefit. The systematic review by
Tleyjeh et al. (2020) discusses the treatment of inflammatory CRS in other disease processes
using an IL-6 receptor blockade with TCZ, and how this treatment may also be beneficial to treat
COVID-19. Campochiaro et al. (2020) tracked the inflammatory marker CRP during their
retrospective study – finding that patients that improved clinically post-TCZ infusion had
significantly lower median CRP levels than those that did not improve (128 versus 186,
respectively, p = 0.038). This level of evidence is moderate at Level III, but still significant data
that curtailing the inflammatory response may be associated with better clinical outcomes. It
would be interesting to investigate whether trending CRP levels or other inflammatory markers
such as IL-6 would be more specific to COVID-19, and to choose one based on the evidence
found as recommendation for practice moving forward.
Route of Administration
Another theme regarding the use of TCZ that emerged within the literature was the route
of TCZ administration. Many of the articles mention a weight-based dose, but neglect to state
what route of administration was used. Others are more specific in their dosing and route, but the
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route for some of the studies varied. The different routes of TCZ administration may or may not
have an impact on the outcomes, and more research needs done. For example, do patients need a
different dose of TCZ if given SQ versus IV? Or would the timing of dosing need to be more
frequent if given SQ? Does the route change the level of absorption and thus change the amount
of inflammatory reduction? Are there more adverse events associated with one route or the
other? These questions warrant further study.
The irregularity of the dosing and varying routes of administration affected the level of
evidence regarding TCZ administration. For example, Klopfenstein et al. (2020) states that the
treatment group of patients received one or two doses of TCZ during the study, but do not state
exact dose or route of administration. In contrast, the systematic review by Alzghari and Acuna
(2020) listed doses between 80 to 600 mg by intravenous (IV) route, but the number of doses
varied.
Menzella et al. (2020) had to tailor their drug formulation and route by drug availability.
The COVID-19 cases in Italy grew exponentially during their study, forcing them to use SQ TCZ
when IV TCZ became unavailable. When no TCZ was available at all, new subjects were made
into a control group (Menzella et al., 2020). Malekzadeh et al. (2020) used only the SQ route for
TCZ administration and used two to three doses ranging from 324 mg to 486 mg, depending on
patient weight. Rossotti et al. (2020) used the IV route exclusively at a dose of 8 mg/kg with a
maximal dose of 800 mg, and a second dose given 12 hours later only if the patient remained
febrile. Others, such as Xu et al. (2020), gave only one 400 mg IV dose of TCZ to all treatment
subjects.
The differences in the route of administration, drug availability, dose strength, and
number of doses varies greatly between some studies and is not mentioned in others. Overall, the
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variation in route of administration contributes to a low level of evidence for this theme. Even
the Level I evidence, such as the systematic review by Alzghari and Acuna (2020), has varying
routes and doses of TCZ given within their included studies. This highlights a gap in the research
and a need for more consistent study to fully examine both the efficacy of the drug itself and to
optimize the details of administration for more reliable, generalizable results.
Concurrent Steroid Use
A third theme that was found within the literature was the concurrent use of
glucocorticoids, such as the steroids dexamethasone and prednisolone, along with TCZ therapy.
The use of steroids also differs between studies and impacts the strength of the results. Menzella
et al. (2020) named glucocorticoids as the only known effective therapy against COVID-19 and
stated that their combined use with TCZ may prevent the need for mechanical ventilation and
improve mortality rates in severe cases. Perrone et al. (2020) also found that mortality rates were
lower for COVID-19 patients that received both TCZ and concomitant corticosteroids. The
difference in mortality rates for the combined therapy was found to be statistically significant at
14 days (Perrone, et al., 2020). This differs from CAR-T therapy, which does not use steroids as
an adjunct with TCZ administration.
Steroid use was part of standard therapy for some studies, such as Mady et al. (2020). In
contrast, Campochiaro et al. (2020) did not allow concurrent steroids to be eligible for TCZ
treatment. Lastly, multiple studies did not mention steroids or, like Klopfenstein et al. (2020),
mention only that some patients received them. Steroid use was inconsistent across studies, and
the types, doses, and routes varied.
The variation in steroid use between studies makes the level of evidence for this theme
low. The studies cited using both TCZ and consistent steroid use all represent Level III evidence.
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This moderate-level evidence produces more questions, since they did not have consistent
dosing, consistent treatment length, and consistent TCZ dosing. Determining the optimal timing
for TCZ treatment also warrants further study – would starting TCZ and steroids together
provide better results, or should one come before the other? The theme of concomitant steroid
use identifies a gap in the research. It would be beneficial to either study the effectiveness of
glucocorticoids alone or keep the use consistent to better evaluate the efficacy of TCZ as an
addition to the therapy regimen.
Safety
Safety was a common theme found throughout the literature review. Due to the public
health emergency, off-label TCZ use as a possible immunomodulatory therapy was suggested for
use in severe COVID-19 cases (Salvati, et al., 2020). Due to the off-label use, many studies
researching its efficacy also simultaneously reported on the drug’s safety profile. Some, such as
the review by Alzghari and Acuna (2020), emphasize the importance of screening for latent TB
before use. This was supported by Dastan, et al., who stated that “reactivation of tuberculosis is
an important challenge” and recommended TB screening every patient eligible for TCZ (2020, p.
5).
Other safety concerns noted were secondary infections post-TCZ treatment. Bacterial
superinfections were listed as a risk by Lan et al. (2020) and recommended further research on
the subject. Malekzadeh et al. (2020) reported that no adverse events related to TCZ occurred in
their treated patients. Campochiaro et al. (2020) reported some bacterial superinfections and
noted that they occurred more often in patients that received higher doses of TCZ.
Other complications noted post-TCZ treatment were a rise in certain liver function tests
(i.e., transaminitis) and a transient neutropenia (Campochiaro et al., 2020). Perrone et al. (2020)

14
reported three cases of allergic events and also mentioned transaminitis, noting that the liver
enzyme elevation was severe in three percent of the studied cases.
Rossotti et al. (2020) found that TCZ therapy was associated with a longer hospital stay
and speculated that it could be from infectious complications. Their article also noted a
significant increase in D-dimer levels despite a decrease in the other CRS-related markers. They
noted that this finding indicates “that the risk of thrombotic complications after treatment may
not be completely reduced” (Rossotti et al., 2020, p. 16). Rossotti et al. (2020) also observed that
a transient decline in respiratory function seen soon after drug administration, and that there is a
window of risk where patients may decompensate following treatment before they turn for the
better.
The level of evidence for the safety of TCZ was moderate. TCZ is not a new drug, which
is beneficial when assessing the risk when using it for COVID-19. Some patients may not
tolerate TCZ treatment – those with already-elevated liver enzymes should be assessed on a caseby-case basis. Those with known latent TB or with concurrent bacterial infections would not
qualify due to the increased risk for worsening infection.
Risk for secondary infection is increased post-TCZ administration, so assessing
individual patient risk in this scenario also needs done. Questions that need more research
regarding COVID-19 would be to determine the timing of administration, as well as if repeated
doses are beneficial, detrimental, or moot. Overall, the safety profile for TCZ was positive, but a
clear risk/benefit analysis needs done on a patient-to-patient basis before administration. Higher
level research on the safety of TCZ use in severe COVID-19 is warranted, along with the role of
prophylactic antibiotics in this patient population.
Literature Recommendations for Use
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The last major theme to come out of the literature is whether TCZ was deemed
efficacious for the treatment of severe COVID-19 infections. Most of the chosen studies
recommended TCZ for use in severe COVID-19 infections. However, two articles did not
recommend its use: Campochiaro et al. (2020) did not find TCZ to be beneficial over standard
treatment with enough evidence to support its use, and Lan et al. (2020) stated that they did not
find that TCZ added any additional value to this patient population. Campochiaro et al. (2020)
represents level IV evidence as a single-facility retrospective cohort study. Lan et al. (2020) is
level I evidence as a systematic review and meta-analysis of seven studies – however they cited
low-quality evidence within the included studies as their main reason for not being able to
recommend TCZ for use until further higher-quality evidence is obtained.
Other articles recommended TCZ use for severe COVID-19 infections, but only with
stipulations: Rossotti et al., (2020) recommended TCZ be used with caution regarding the
transient decline in respiratory status and potential for adverse secondary infections. Menzella et
al. (2020) found TCZ use effective in the subgroup of patients with major respiratory impairment
but echoed the need for future studies regarding safety and superinfection. Malekzadeh et al.
(2020) found that TCZ had significant impact on clinical parameters and may be especially
useful if administered early in the respiratory decline.
Price et al. found that TCZ seemed to decrease mortality in patients demonstrating CRS
with COVID-19, but that a “more precise identification of predictors of disease progression may
help establish the ideal time for tocilizumab treatment” (2020, p. 1407). Timing was also noted
as important by Dastan et al. (2020), stating that it should be administered early in the disease
course, before the clinical decline. Salvati et al. (2020) found that TCZ promoted earlier vascular
pulmonary recovery but that more research needs done to know if this is a transient positive
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outcome or if it would have a greater impact on long-term survival. The level of evidence found
in the articles recommending TCZ use with stipulations were mainly level III non-controlled
trials or level IV retrospective cohort studies. They cited early administration as their primary
stipulation and requested further study of long-term outcomes.
Seven of the fifteen selected articles recommended the use of TCZ in severe COVID-19
infections within the setting of a global health emergency. Alzghari and Acuna (2020) state that
TCZ should be approved for compassionate use until further research addressing its safety and
efficacy is done. Xu et al. (2020) found TCZ to improve the clinical outcomes in COVID-19
patients and recommended it as an effective treatment.
TCZ was found to reduce the risk for mechanical ventilation and showed some
association between its use and lower mortality in the study by Tleyjeh et al. (2020). The metaanalysis by Zhao et al. (2020) observed a significant difference in mortality between TCZ and
control groups, suggesting that TCZ therapy is potentially effective against severe COVID-19.
TCZ treatment reduced ICU admissions and mortality in the study by Klopfenstein et al.
(2020) and was recommended for use. Mady et al. (2020), despite acknowledging the need for
more research, also recommended TCZ as an adjunct therapy in evolving coronavirus disease.
Lastly, Perrone et al. (2020) found that TCZ use significantly reduced mortality rates at 30 days
and recommended it for use while continuing phase three trials on the subject.
The level of evidence supporting the use of TCZ was moderate, and included multiple
level I studies, such as the systematic reviews and meta-analyses by both Alzghari and Acuna
(2020) and Zhao et al. (2020). However, most of the included studies came from lower-level
evidence such as level IV retrospective cohort studies or level III non-controlled trials. Some,
like Mady et al. (2020), lacked a control group. However, the setting of global health crisis has to
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be taken into account. Many of these trials were less-than-ideal due to the critical nature of the
pandemic, and the recommendation to use a drug in a crisis may vary versus recommendations
for its use in a less-dire scenario.
Summary of Evidence and Literature Reviewed
These studies were done on an emergent basis, and the findings must be interpreted as
such. The quality and design of many of the studies were lacking. Shortages of TCZ impacted
the research - some trials were forced to change the route of administration mid-study, as well as
adding a control group when they ran out of drug altogether (Menzella et al., 2020). Perrone et
al. (2020) added so many patients that they ended up creating a validation cohort after the study
had already begun. These changes and variations in studies made generalization more difficult
and made their results harder to interpret.
The quality of evidence was moderate, with some studies not having enough patients to
be fully powered. Multiple variables were not consistent throughout, such as what qualified as
“standard treatment” or what was considered “severe” COVID-19. These discrepancies need
taken into consideration when appraising the research and the recommended outcomes.
The need for effective treatment may also skew recommendations. Goals of care, such as
reducing the number of intensive care admissions or reduction in the need for mechanical
ventilation, become more vital when hospital resources are scarce, thus any small benefit may be
of greater impact in an emergency.
Overall, TCZ was found to be recommended for use to treat severe COVID-19 infection.
In the setting of a global health crisis, recommendation for TCZ use may be warranted to attempt
to improve patient outcomes and relieve some of the strain on the healthcare system. However,
one must consider the low-level evidence, inconsistent study variables, and notable gaps in
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research when making clinical decisions regarding its use. A conceptual model that uses a
feedback loop will be beneficial for this situation so that recommendations can change as more
research is completed on this topic.
Conceptual Framework
Johns Hopkins Nursing Evidence-Based Practice Model
The Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) Model (2017) was
selected for this inquiry for multiple reasons. The first reason it was chosen was due to its
simplicity and similarity to the structure of the literature review itself. The model uses a threestep process that aligns well with the structure of this inquiry – practice question, evidence, and
translation. Within the first step of the JHNEBP Model, a clinical practice question is developed,
and the problem is defined. Stakeholders, as well as the team to conduct the inquiry, are
identified and a schedule is then created.
The next step of the JHNEBP model examines the evidence by conducting a literature
search, a review of the current literature, and an appraisal of the quality of evidence. Afterwards,
a synthesis of the evidence is performed. The results of the synthesis help guide practice
recommendations and are cultivated into a plan for practice change.
Once an action plan is developed based on the evidence recommendations, support and
resources are identified and obtained. The plan for clinical practice is then implemented. Over
time, the outcome of the practice changes will be evaluated, reported to the stakeholders, and
findings disseminated. Once the process change reaches this point in the model, the action plan
can be updated and changed as the outcomes are evaluated.
This framework was also selected because it can be continuously updated as new
evidence appears. The cyclical nature of this model allows for more changes to be put into place
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as the outcomes are evaluated. This is especially important for this topic, as the science regarding
COVID-19 and its treatment is new, ongoing, and evolving.
The themes found within the literature review can all be assessed using this model as
more research emerges – the route of administration, the use of concurrent steroids, and the
overall drug safety profile for this patient population can all be evaluated and reevaluated using
this model. As more evidence is collected, the recommendations may change, leading to different
practice changes. This model allows for that, with the translation and dissemination step at the
end, which can circle you back to the literature review.
Lastly, this framework takes both internal and external factors into account. Internal
factors that may play a part in this clinical problem may include medication availability,
appropriate clinical identification of eligible patients, and staffing. External factors could include
things such as COVID-19 outbreak status in the area and federal regulations regarding
medication use, such as FDA approval. Taking in all factors that may influence a clinical
problem is an important factor in any EBP model, but especially important in one that involves a
global pandemic. Permission to utilize the JHNEBP Model was granted by Johns Hopkins
Nursing. The JHNEBP Model and its respective steps are outlined in Appendix A.
Conclusions, Implications, and Recommendations for Nursing
Introduction
The purpose of this literature review was to evaluate the impact of TCZ therapy for
severe COVID-19 infections and to assess the benefit of its use for this patient population. This
section will conclude the inquiry, present implications, and give recommendations for practice
regarding its use.
Conclusions
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The pandemic stemming from the novel coronavirus and resulting COVID-19 infections
is perhaps the largest event to affect the global population in nearly a century. The effects on
humanity and the healthcare system are ongoing, and evaluating effective therapeutic
interventions are still vital to the treatment of these patients. A review of the literature highlights
the hyperinflammatory response by the immune system as a treatment target. TCZ treatment
aims to prevent or reduce the inflammatory cascade seen in clinically worsening patients with
COVID-19. Finding a beneficial way to use TCZ is important for patient morbidity and
mortality, as well as secondarily conserving hospital resources.
Implications for Nursing
The effect that this pandemic has had on the nursing profession has been monumental.
Staffing shortages are widespread, as nurses leave the profession in droves. The physical and
emotional toll has left many nurses struggling. A key element of this struggle has been the lack
of treatment for this patient population. Having evidence-based recommendations in place will
help create a more solid treatment plan.
Nursing will play a key role in TCZ administration, and education will need given to
those administering this drug. TCZ administration will be delivered intravenously via infusion
over sixty minutes. Before infusion, nurses should confirm that the patient has been screened for
infections such as tuberculosis and hepatitis B, and that the ordering clinician does not suspect
any concurrent bacterial infection. The patient should not have an absolute neutrophil count
(ANC) below 2000/mm³ or a transaminitis five-fold above normal.
The nurse should inspect the drug for any leaking or visible particulates before
administration. TCZ should be given on its own dedicated IV line and not mixed with any other
medications. The patient’s temperature, blood pressure, and pulse should be obtained before
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infusion, after the start of the infusion, and at the end of the infusion. Lab monitoring should be
done daily to watch for worsening liver function or a developing bacteremia. A daily complete
metabolic panel (CMP) or equivalent should be ordered.
The nurse should watch for signs of hypersensitivity or allergic reactions, such as hives
or angioedema during and post-infusion. Close monitoring of the patient’s respiratory status is
also warranted – the nurse should notify the ordering physician if the patient is having signs of a
reaction or if their respiratory condition worsens post-administration, such as increasing oxygen
needs, or increased work of breathing occurs. Nursing should also be aware of the risk for
secondary infections, and report any new fever, rigors, or patient status changes to the provider.
Lastly, nursing will also need to educate the patient or the family about TCZ administration, why
the drug is being given, and what complications can occur.
An algorithm for patient inclusion would be beneficial, both for the providers to know
when to order the drug, and for the nurses to explain to the patients and family about when and
why their family member qualifies to receive TCZ. Collaboration and communication between
the healthcare team members is key to implementing this treatment intervention successfully.
Further literature review and continued evaluation via the JHNEBP Model can create a
transition from crisis-based intervention to evidence-based intervention. Having a treatment
algorithm in place will help streamline the process for nursing and providers alike. Improving
patient outcomes and reducing hospital strain will also have a positive impact on nursing.
Recommendations
Due to the evolving nature of this topic, a final literature search was conducted in
October of 2021. This search was conducted specifically to look for updated recommendations
on the use of TCZ in this setting. This search was done using the Cochrane Database of
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Systematic Reviews and limited to evidence found within 2021. The Cochrane Review by Ghosn
et al. (2021) was found during this search.
Ghosn et al. (2021) now found high levels of evidence to support TCZ use and a
reduction in all-cause mortality at 28 days. Ghosn et al. ended their review stating, “We are
confident that tocilizumab reduced the number of deaths (from any cause) at 28 days.” (2021,
p.4). They state that TCZ treatment “probably reduces slightly the number of serious unwanted
effects, such as life-threatening conditions or death” (Ghosn et al., 2021, p. 4). The evidence to
support clinical improvement or longer-term mortality reduction currently remains low to
moderate. This living systematic review represents the most up-to-date evidence available and
supports the prior literature regarding TCZ treatment of severe COVID-19 infections (Ghosn et
al., 2021).
The recommendations for emergency drug use during a pandemic will always be
evolving. The ability to use TCZ effectively will depend first and foremost on drug availability.
Conserving doses should be a high priority and makes finding the right target population very
important. The first steps in the JHNEBP Model involve creating an interprofessional team to
address the clinical problem. A group of providers, nurses, and pharmacists should all be
involved in the action plan, with well-defined ways to communicate information and set dates to
evaluate and reevaluate the treatment plan.
The second and third parts of the JHNEBP Model involve using the evidence to create an
action plan. This inquiry provides a starting point for these steps in the model. According to the
evidence, patients should be considered for TCZ treatment if hospitalized with a diagnosis of
COVID-19 confirmed via positive nasal pharyngeal reverse transcriptase Polymerase Chain
Reaction (RT-PCR) test (Campochiaro et al., 2020). The primary inclusion criteria for TCZ aim
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to identify those patients that are showing signs of increased inflammatory activity or worsening
disease symptoms. The chosen lab markers for consideration includes elevated CRP and elevated
D-dimer (Mady et al., 2020). Elevated serum levels of IL-6 levels as well as elevated ferritin or
fibrinogen may also be considered (Salvati et al., 2020).
Other findings for consideration are if the patient is febrile and has a respiratory rate of
greater than 30 breaths per minute (Malekzadeh et al., 2020). If they are short of breath,
requiring oxygen delivery via nasal cannula, or if their partial pressure of oxygen (PaO2) to the
fraction of inspired oxygen (FiO2) ratio (PaO2:FiO2) is less than or equal to 300 mmHg, they
should also be considered for TCZ treatment (Campochiaro, 2020). Worsening findings on chest
X-ray or computed tomography (CT) scan could also be considered on a patient-by-patient basis
(Campochiaro, 2020).
The inclusion criteria for this action plan needs to be the most fluid, due to the shifting
availability of the drug. Many of the studies cited shortages and that is being seen in practice.
Therefore, revaluating the target population and narrowing the inclusion criteria may be
necessary if there are weeks with limited supplies. Pharmacy must be involved with this action
plan and supply levels evaluated at agreed-upon intervals.
There must be a hierarchy of inclusion criteria depending on availability. For example, if
supplies are plentiful, then the net of inclusion could include any patient hospitalized with
symptomatic COVID-19 infection listed above. However, if supplies are lacking, finding the
target population of patients that are showing signs of increasing inflammation but are not yet
critical may be of the most benefit. There is less evidence for TCZ treatment if the patient is
already critically ill (Mady et al., 2020).
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During a time of scarcity, inclusion criteria must be limited. Patients on nasal cannula
may be considered for other oral treatments (such as the oral Janus kinase-inhibitor baricitinib),
reserving the IV TCZ for those that cannot breathe well enough to consistently take the
medication by mouth (Stasi et al, 2020). Menzella et al. (2020) used tighter inclusion criteria,
requiring the patient to be on non-invasive ventilation with at least 60% FiO2, and a PaO2:FiO2
ratio greater than 100mmHg but less than 200mmHg. Inclusion criteria and available options for
each patient needs to be a continuing conversation between pharmacy and providers.
Exclusion criteria for TCZ administration is more stable within this action plan. The
major factor excluding patients from being able to receive TCZ treatment was that of risk of
harm. TCZ risk outweighs the benefit in certain scenarios. Anyone with a history of
hypersensitivity to TCZ or its components were therefore excluded (Perrone et al., 2020).
One major exclusion criterion involves the risk of secondary infection, therefore
excluding patients with signs of a concomitant bacterial infection (Campochiaro, 2020). Latent
tuberculosis was also considered a factor for exclusion (Dastan et al., 2020). A history of
infections such as hepatitis B, hepatitis C, HIV, or any concern for bone marrow suppression
were also excluded from TCZ treatment. There was also transient documentation of bowel
perforation post-TCZ administration, so some excluded those with active diverticulitis (Perrone
et al., 2020). This same reasoning excluded those with active peptic ulcer disease in certain
studies (Malekzadeh et al., 2020).
Another group of patients that have elevated risk of harm versus benefit to TCZ treatment
were those with organ impairment. Some studies excluded those with chronic renal impairment –
for example, Dastan et al. (2020) excluded those with a glomerular filtration rate (GFR) of less
than 30 mL/min. Liver impairment was most often excluded, and the most common exclusion

25
criteria for the liver was an existing transaminitis of five-fold above the upper normal limit
(Campochiaro et al., 2020). The level of impairment and the risk versus benefit should be done
on a patient-by-patient basis, depending on the setting, patient history, and their clinical picture.
The TCZ dose amount and whether to give a second dose is also very dependent on drug
availability, and again why this action plan needs a cyclical framework. IV was the preferred
administration route. Subcutaneous TCZ was also used and in some studies was found to have
positive outcomes, so should be considered if the IV formulation is not available (Malekzadeh et
al., 2020).
Within the literature, one 400 mg IV dose was often used, and would be the chosen dose
if supplies are scarce (Campochiaro, 2020). A second dose was often given. Some considered a
second dose only for those with an elevated body mass index (BMI) (Price et al., 2020). Other
studies only gave a second dose if the patient had no change or worsening respiratory status, at
the discretion of the provider (Perrone et al., 2020). The preferred method for this action plan
would be weight-based dosing of 8mg/kg, with a maximum dose of 800 mg with two
consecutive infusions, 12 hours apart (Mady et al., 2020).
A limited number of providers with TCZ ordering capability should be designated to
keep supplies in check. There will need to be a pharmacy lead on daily that evaluates dosing and
inclusion/exclusion criteria. There should be a green/yellow/red light hierarchy of inclusion
criteria that is updated weekly, to determine which inclusion criteria is being used that week and
should shift with the supply. Green light inclusion would be all symptomatic hospitalized
patients without exclusion criteria. Yellow light inclusion would be to shift the inclusion criteria
to those with escalating oxygen needs and increasing inflammatory markers. Red light inclusion
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would trigger patient-by-patient consideration, dosing considerations, and the use of alternative
routes and medications if needed.
Lastly, treatment recommendations for special populations will always need to be
individualized. This includes those that are immunocompromised, pregnant, breastfeeding, those
that arrive already critically ill, among others. A monthly meeting between the providers and
pharmacists should be arranged to discuss special cases and outcomes, as well as updated
literature on the subject. Each piece of the action plan should be evaluated within the JHNEBP
Model at this meeting, and changes made as warranted.
Summary
In the setting of a global pandemic, all viable treatment options should be explored. The
elevated inflammatory response seen in severe COVID-19 infections is linked to higher
mortality. TCZ has been used to stave off the cytokine storm seen in other inflammatory
processes. Inhibiting the inflammatory cytokine IL-6 to curtail the resulting CRS and improve
patient outcomes is the aim of TCZ treatment. Following this scholarly inquiry, TCZ treatment is
recommended for use at this time to treat severe COVID-19 infection.
Additional research is needed to establish higher level evidence and more detailed
treatment recommendations for TCZ administration. Many other questions also warrant deeper
investigation, such as clarifying the use of concurrent steroids, which inflammatory markers are
best for trending COVID-19 infection, whether longer courses of TCZ might be beneficial, and
the exploration of other emerging monoclonal therapeutic options. This is an evolving situation,
and it should be continuously reevaluated.
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Eslaminejad, A., Heshmatnia, J.,
Sadeghi, M., Nadji, S., A.,
Dastan, A., Baghaei, P.,
Varahram, M., … Tabarsi, P.
(2020). Promising effects of
tocilizumab in COVID-19: A
non-controlled, prospective
clinical trial. International
Immunopharmacology, 88, 1-7.
doi.org/10.1016/j.intimp.2020.10
6869
CINAHL

“Data is
particularly
needed on
treatments able
to reduce
mortality and the
number of
critically ill
patients” (p.
397).

Population/
Sample/
Setting
Dr. Masih
Daneshvari
Hospital in
Tehran, Iran.
76 assessed, 42
selected. All
positive for
COVID-19.
Inclusion: Severe
(RR > 30, SpO2
< 90,
progressive lung
infiltrate, critical
(ICU or
intubated), no
improvement for
over 72h
Exclusion:
pregnant,
bacterial
infection, use of
antiinflammatory
agents, CKD,
liver disease, did
not receive 72h
of care.

Study Design/
Variables/
Instruments
Prospective
study, noncontrolled trial.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

72h in, 20 were
severe stage and
22 critical.
No statistically
significant
difference in
time-to-death in
severe vs. critical
patients (p =
0.06) but
survival rate
higher in severe
group.

3 patients
experienced
adverse
effects postTCZ

IV

One 400mg
TCZ dose
given.

Severe TCZ
patients had
better
outcomes
which may
suggest
greater
efficacy of
earlier
administratio
n of TCZ.

Standard care
was oxygen
delivery and an
antiviral drug.
Patients
evaluated for 28
days.
Clinical
improvement:
weaning from
oxygen/dischar
ge from
hospital. Xray
and CT done at
baseline and
Day 14.
Statistical
analysis of
survival via
Kaplan-Meier
estimator.

28 patients
demonstrated
significant
improvement on
lung imaging.
Overall mortality
rate was 49% on
patients admitted
to ICU.

Limited by
small size and
lack of
control group.
“There may
be an ideal
time point for
initiating
tocilizumab
therapy, and
all efforts
should be
made to
administer it
during the
early stages
of SARSCoV-2
infection
before
deterioration
of clinical
conditions”
(p.5).

No steroid
use.
No
statistically
significant
improvemen
t.
CRS occurs
after
inflammator
y cascade
activation
TCZ binds
to IL-6
receptors
and inhibits
signal
transduction
Screen for
latent TB
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Klopfenstein, T., Zayet, S.,
Lohse, A., Balblanc, J., Badie, J.,
Royer, P. Toko, L., Mezher, C.,
Kadiane-Oussou, N.J., Bossert,
M., Bozgan, A., Charpentier, A.,
Roux, M., Contreras, R.,
Mazurier, I., Dussert, P., Gendrin,
V., & Conrozier, T. (2020).
Tocilizumab therapy reduced
intensive care unit admission s
and/or mortality in COVID-19
patients. Medecine et Maladies
Infectieuses, 50, 397-400.
doi.org/10.1016/j.medmal.2020.0
5.001

To study whether
TCZ is an
effective
treatment for
COVID-19.

Science Direct

Population/
Sample/
Setting
Nord FrancheComte Hospital
in France.
20 patients in
TCZ group, 25 in
control.
Inclusion: no CI
to TCZ, failure
of standard
treatment,
elevated
inflammatory
markers, >25%
lung damage on
CT scan, oxygen
needs >/=
5L/min
Exclusion: those
with only
moderate disease
presentation and
those that
received other
meds not
normally in
standard
treatment.

Study Design/
Variables/
Instruments
Retrospective
case-control
study with
control group.
Endpoint was
determined to
be death and/or
ICU admission.
Groups were
compared via
Charlson
comorbidity
index, as well
as statistical
analyses.
No statistical
differences
between groups,
however the
TCZ group had
a higher
comorbidity
index (p =
0.014) and
higher age (p =
0.036).
No statistical
differences
between groups
at admission.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

Endpoint of
death or ICU
admission,
however, was
higher in the
standard group
than TCZ group
(72% vs 25%, p
= 0.002) and the
standard group
needed
mechanical
ventilation more
often (32% vs
0%, p = 0.006).

Limitation of
small sample
size and
retrospective
design.

Positive
outcomes

III

Mortality
difference not
statistically
significant but
higher in
standard group
(48% vs 25%, p
= 0.066).

The data
“strongly
suggests that
TCZ may
reduce the
number of
ICU
admissions
and/or
mortality in
patients with
severe SARSCoV-2
pneumonia”
(p.398).
“TCZ could
be key in the
treatment of
COVID-19
cases to
reduce ICU
admissions”
(p.397).

Cytokine
storm causes
the multiorgan failure
seen in this
population
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Lan, S., Lai, C., Huang, H.,
Cheng, S., Lu, L., & Hsueh, P.
(2020). Tocilizumab for severe
COVID-19: A systematic review
and meta-analysis. International
Journal of Antimicrobial Agents,
56, 1-7.
doi.org/10.1016/j.ijantimicag.202
0.106103
Science Direct

To “assess the
efficacy of
tocilizumab for
the treatment of
severe
coronavirus
disease 2019
(COVID-19)”
(p.1).

Population/
Sample/
Setting
592 total
patients: 240 in
TCZ groups and
352 control
groups.
Inclusion:
comparing TCZ
against control
regarding at least
one of the
following: allcause mortality,
ICU admission,
and requirement
of mechanical
ventilation.
Exclusion: Case
reports, studies
without a
control, studies
that did not
report a required
outcome.

Study Design/
Variables/
Instruments
Systematic
Review and
Meta-Analysis
of seven
retrospective
studies.
Done in
accordance with
the Preferred
Reporting Items
for Systematic
Reviews and
Meta-Analyses
(PRISMA).
Two authors
assessed articles
separately to
avoid bias.
Pool analysis
was done on the
seven studies.
Bias was
assessed using
the NewcastleOttawa scale.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

All-cause
mortality rate of
the TCZ group
was 16.3%
which was lower
than the 24.1%
of the control
group, but not
statistically
significant (RR =
0.62).

Limitation:
the number of
doses and
route of
administratio
n varied
between
studies.

No better
outcome for
TCZ group
vs control
group

III

5 studies
reported ICU
admission and 3
reported
ventilator
requirements all reported
similar risks
between groups.
“Tocilizumab
could not
provide any
additional
benefit for the
clinical outcome
of severe
COVID-19”
(p.2).

TCZ group
had higher
Charlson
comorbidity
index and
higher
inflammatory
markers at
baseline (p <
0.00001)
Other studies
that matched
their groups
better showed
better
outcomes for
the TCZ
groups.
Timing/dosin
g could affect
outcome.
Bias rated 6
out of 7 scale.

Studies
carry heavy
limitations.
“The
tocilizumab
group had
more severe
clinical
outcomes
compared
with the
control
group and
may explain
why no
additional
benefit of
tocilizumab
was found in
this metaanalysis”
(p.6).
IL-6 is most
important
cytokine in
CRS
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Mady, A., Aletreby, W.,
Abdulrahman, B., Lhmdi, M.,
Noor, A., Alqahtani, S., Soliman,
I., Alharthy, A., Karakitsos, D., &
Memish, Z. (2020). Tocilizumab
in the treatment of rapidly
evolving COVID-19 pneumonia
and multifaceted critical illness:
A retrospective case series.
Annals of Medicine and Surgery,
60, 417-424.
doi.org/10.1016/j.amsu.2020.10.0
61
Science Direct

To analyze the
critical course of
critically ill
COVID-19
patients and
evaluate whether
IV TCZ would
be associated
with more
favorable patient
outcomes.

Population/
Sample/
Setting
King Saud
Medical City in
Riyadh, Saudi
Arabia.
61 patients met
inclusion criteria.
Inclusion: ICU
admission with
at least one of:
MV, RR > 30,
SpO2 < 90% on
RA, P:F ratio <
300 and given
TCZ.
Exclusion:
pregnant, known
immune
suppression, CI
to TCZ use.

Study Design/
Variables/
Instruments
Retrospective,
single-arm,
single-center
observational
study.
All patients got
antivirals,
antibiotics,
steroids, and
enoxaparin
(unless CI).
All patients
received 2
doses of TCZ
during the
study.
Data was
statistically
analyzed as
appropriate.
Proportional
hazard model
was adjusted for
variables
deemed
important.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

Mortality rates
were 24.6% on
day 14 post-ICU
admission and
31.1% on day
30.

“The
administratio
n of TCZ per
se as an
adjunct
therapy did
not have any
effect of the
mortality of
critically ill
COVID-19
patients”
(p.419).

Steroids

IV

TCZ was found
the be a safe
adjunct therapy
but no control
group to
compare
outcomes.
Comparison
between pts
receiving MV
and non-MV had
significantly
longer ICU and
hospital stays (p
= 0.04 and p =
0.01).

Study was
small and
underpowere
d.
With no
control group,
the results
were not very
helpful.

used.
Secondary
infections
were not
correlated
with
mortality.
Higher
comorbidity
and critical
illness in
this study
compared to
some others.
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Malekzadeh, R., Abedini, A.,
Mohsenpour, B., Sharifipour, E.,
Ghasemian, R., Javad-Mousavi,
S. A., Khodashahi, R., Darban,
M., Kalantari, S., Abdollahi, N.,
Salehi, M. R., Hosseinabadi, A.
R., Khorvash, F., Valizadeh, M.,
Dastan, F., Yousefian, S.,
Hosseini, H., Anjidani, N. &
Tabarsi, P. (2020). Subcutaneous
tocilizumab in adults with severe
and critical COVID-19: A
prospective open-label
uncontrolled multicenter trial.
International
Immunopharmacology, 89, 1-11.
doi.org/10.1016/j.intimp.2020.10
7102
Pub Med

To evaluate the
use of SQ TCZ
in adult patients
with severe or
critical COVID19 on patient
outcomes

Population/
Sample/
Setting
8 tertiary care
centers in Iran.
126 patients, 86
severe and 40
critically ill.
Inclusion:
febrile, cough,
RR > 30, O2 sat
< 93 on RA, IL-6
level of 3x
normal
Exclusion: hx of
hepatitis,
immune
suppression, CI
to TCZ,
pregnancy,
concurrent
infection
Wt-based doses
of SQ TCZ.
All received
antivirals,
antibiotics, and
interferon beta1a

Study Design/
Variables/
Instruments
Prospective,
multi-center,
uncontrolled
study.
Outcomes
measured were
all-cause
mortality,
oxygen support
use, O2
saturation, RR,
and lab values.
Drug safety was
also evaluated.
Patients
followed up
until discharge
or death.
Assessed
change on a 6point scale from
1) no oxygen to
6) death.
All data
between groups
were
statistically
analyzed.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

All-cause
mortality was
much higher
(60%) and
statistically
significant in
critical patients
vs severe
patients (p <
0.001).

Better results
in severe
patients and
high
mortality of
critical
patients
suggest that
earlier TCZ
may provide
more benefit.

No steroids
used.

IV

No TCZ-related
adverse events
occurred.
Rapid
improvements to
RR, body
temperature, and
blood
oxygenation
were seen after 3
days of TCZ and
sustained
throughout
treatment.
Results with high
dose SQ TCZ
were similar to
that of IV TCZ.

Uncontrolled
design was a
limitation.
“Subcutaneou
s tocilizumab
might be
capable of
reducing the
risk of death,
particularly if
used the in
the early
stages of
respiratory
failure” (p.8).
SQ TCZ may
be an
appropriate
substitute for
IV if the IV
TCZ is not
available.

Cytokine
storm.
SQ TCZ
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Menzella, F., Fontana, M.,
Salvarani, C., Massari, M.,
Ruggiero, P., Scelfo, C., Barbieri,
C., Castagnetti, C., Catellani, C.,
Gibellini, G., Falco, F., Ghidoni,
G., Livrieri, F., Montanari, G.,
Casalini, E., Piro, R., Manusco,
P., Ghidorsi, L., & Facciolongo,
N. (2020). Efficacy of
tocilizumab in patients with
COVID-19 ARDS undergoing
noninvasive ventilation. Critical
Care, 24, 589.
doi.org/10.1186/s13054-02003306-6
CINAHL

To evaluate the
safety and
efficacy of TCZ
in patients with
COVID-19
ARDS on
noninvasive
mechanical
ventilation.

Population/
Sample/
Setting
Pulmonary unit
of Azienda USL
of Reggio Emilia
– IRCCS.

Study Design/
Variables/
Instruments
Retrospective
case-control
study, control
group.

79 patients with
severe/
worsening
disease. 41 in
the TCZ group,
38 in control
group

TCZ route
determined by
availability (28
IV, 13 SQ)

Inclusion: pts all
needed NIV and
had P:F ratios of
100 to 200
despite Venturi
mask.

Improvement
measures: P:F
ratio increased
by 30%, FiO2 <
50%, RR < 30,
PEEP < 8, and
able to keep TV
> 5ml/kg body
weight with PS
< 10.

The control
group
represented
patients admitted
when no TCZ
was available.

TCZ given at
the start of NIV.

Outcomes
measured: inhospital
mortality,
intubation, postTCZ infections.
Data was
statistically
analyzed.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

CRP levels
significantly
lower in TCZ (p
= 0.02 and p =
0.001).

TCZ group
significantly
younger,
lower
Charlson
comorbidity
index, got
more HCQ

Control
group

III

Overall
probability of
dying
significantly
lower in both
TCZ groups (p =
0.092).
Probability of
dying or being
intubated was
also significantly
lower in the TCZ
groups (p =
0.036).
Adjusted for sex
and age,
significantly less
chance of
intubation and
death in TCZ
groups but not
overall mortality
(p = 0.022 vs. p
= 0.192)

Results lost
significance
in the SQ
group versus
control,
implying that
IV may be
more
effective.
“Results
suggest that
TCZ could be
an effective
therapeutic
option for the
treatment of
critically ill
COVID-19
patients
receiving
NIV” (p. 7).
Small sample
size

IV vs SQ
Secondary
infections
did not
affect
mortality
Heterogeneo
us route of
TCZ may
have
muddied
results
Suggests
combining
TCZ and
steroids for
better
treatment.
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Perrone, F., Piccirillo, M.C.,
Ascierto, P.A., Salvarani, C.,
Parrella, R., Marata, A.M.,
Popoli, P., Ferraris, L., MarroccoTrischitta, M., Ripamonti, D.,
Binda, F., Bonfanti, P., Squillace,
N., Atripaldi, L., … & Chiodini,
P. (2020). Tocilizumab for
patients with COVID-19
pneumonia. The single arm
COVID-19 prospective trial.
Journal of Translational
Medicine, 18, 405.
doi.org/10.1186/s12967-02002573-9
CINAHL

To evaluate the
efficacy of TCZ
“while
controlling the
highly increasing
off-label use of
the drug” (p. 2).

Population/
Sample/
Setting
Multicenter
Italian trial, 301
patients.
59.8% received
TCZ
Validation
cohort added due
rapidly
increasing pts –
920 patients
Inclusion: O2 sat
</= 93 on RA or
requiring
NIV/MV
(intubated within
24 hours of
inclusion)
Exclusion:
bacterial
infection,
GI/other CI to
TCZ, ALT/AST
> 5x normal, low
neutrophils/
Platelets

Study Design/
Variables/
Instruments
Single-arm
study with 2%
14 day and 35%
one-month
mortality rate as
null hypothesis
and a TCZ
group 10%
reduction at 14
and 30 days as
alternative
hypothesis.
Data was
statistically
analyzed for
both cohorts
separately

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

TCZ
significantly
lowered need for
respiratory
support (p = 0.03
and 0.08 at 14d
and 30d).

Variable
delay
between
registration
and drug
administratio
n due to
availability

Study
“supports
the use of
tocilizumab”
(p. 9).

III

Null hypothesis
rejected at 30d
but not at 14d (p
< 0.001 and p =
0.52).
Mortality rates
higher for older
patients, those
with lower P:F
ratios.
Mortality rates
lower for those
treated with both
TCZ and steroids
and statistically
significant at 14d
(p = 0.004).

Younger and
critical
patients given
preferential
treatment.
“The possible
effect of
tocilizumab
might be
greater
among
patients not
requiring
mechanical
ventilation”
(p. 5).
Single-arm
study limited
ability to
draw
conclusions
Selection and
immortal
time bias

Missing data
due to the
massive
influx of
patients
Steroid use
Addresses
safety and
exclusion
criteria
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Price, C., Altice, F.L., Shyr, Y.,
Koff, A., Pischel, L., Goshua, G.,
Azar, M.M., Mcmanus, D., Chen,
S-C., Gleeson, S., Britto, C.,
Azmy, V., Kaman, K., Gaston,
D., Davis, M., Burello, T., Harris,
Z., Villanueva, M.S., AounBarakat, L., … & Malinis, M.
(2020) Tocilizumab treatment for
cytokine release syndrome in
hospitalized patients with
coronavirus disease 2019. Chest
journal, 158, 4.
doi.org/10.1016/j.chest.2020.06.0
06
CINAHL

To determine if
tocilizumab
treatment could
positively impact
patients
hospitalized with
COVID-19

Population/
Sample/
Setting
Single hospital
study in
Connecticut,
USA.
Inclusion: severe
disease: >/= 3L
oxygen, critical:
needing MV, and
evolving CRS
Disease severity
determined at
admission

Study Design/
Variables/
Instruments
Observational
study, chart
review
239 patients,
21-day
observation
period, 21-day
follow-up
period. 104
deemed severe
at admit.
13-point scale
measured
changes in
oxygenation
status
Measured over
14 days

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

Severe disease:
higher mortality
(p < 0.001), need
for MV (p <
0.001), longer
time spent on
MV (p = 0.003).

Early
administratio
n may slow
disease
progression
and
monitoring of
CRP/CRS
biomarkers
may be
helpful

Race
differences
in mortality

IV

Reducing
need for MV
helps
hospitals
cope with
patient surge

Steroids
may be
useful

Pt surge, but no
parallel surge in
the need for MV
during the study
Survival
significantly
lower in white
patients vs Black
and Hispanic pts,
(p = 0.002).
“use of
tocilizumab may
result in lowerthan-expected
mortality in a
subgroup of
patients with
evidence of
CRS” (p. 1407)

Elevated
DDimer
levels may
indicate that
TCZ only
helps part of
the CRS state
Survival rate
in this TCZ
group was
higher than
other studies

Unable to
establish
causality
No adverse
events with
TCZ

D-dimer
levels
icreased
Treating
CRS was
focus of
therapy
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Rossotti, R., Travi, G., Ughi, N.,
Corradin, M., Baiguera, C.,
Fumagalli, R., Bottiroli, M.,
Mondino, M., Merli, M., Bellone,
A., Basile, A., Ruggeri, R.,
Colombo, F., Moreno, M.,
Pastori, S., Perno, C.F., Tarsia, P.,
Epis, O.M., & Puoti, M. (2020).
Safety and efficacy of anti-il6receptor tocilizumab use in severe
and critical patients affected by
coronavirus disease 2019: A
comparative analysis. Journal of
Infection, 81, 11-17.
doi.org/10.1016/j.jinf.2020.07.00
8
CINAHL

“To evaluate the
efficacy of TCZ
in severe and
critical COVID19 subjects
comparing
survival and
hospital
discharge with
controls matched
for disease
severity” (p. 12).
To evaluate the
safety of TCZ in
terms of clinical
recovery and
infectious events

Population/
Sample/
Setting
Hospital in
Milan, Lombardi
Region, Italy

Study Design/
Variables/
Instruments
Retrospective,
single-center
analysis

74 patients in
TCZ group, 148
matched controls

Chinese
Guidelines for
management of
COVID-19
determined
severity

Inclusion: RR
>/= 30, O2 sat
</= 93 on RA, or
P:F ratio </=
300, intubation,
ICU treatment
Exclusion: ALT
> 5x normal, low
neutrophils or
platelets,
bacterial
infection, GI CI
to TCZ

Clinical/lab
features
assessed at
baseline and
Days 1, 3, 5, 7.
Each TCZ
patient had 2
matched
controls:
age/sex/severity
as well as P:F
ratio, Charlson
comorbidity
index, time to
symptoms and
admission
Data was
statistically
analyzed

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

No significant
differences
between TCZ
and their
matched controls

“This study
confirms the
potentially
effectiveness
of TCZ on
COVID-19 –
especially in
critically ill
patients” (p.
17).

Selection
bias cannot
be ruled out

III

Significant
survival
advantage of
TCZ over control
(p = 0.035)
TCZ associated
with longer
hospital stay (p
= 0.019).
DDimer
continued to rise
even in the TCZ
group
The sharp rise in
IL-6 after TCZ
could lead to
rapid decline due
to hyperinflammation

Longer
hospital stay
may be due to
respiratory or
infectious
complications
“Our data
indicate that
the risk of
thrombotic
complications
after
treatment
might not be
completely
reduced” (p.
16).
Concurrent
steroid use
could
prevent
worsening
CRS after
TCZ

Steroid use
D-dimer >
1.5 mcg/mL
was
considered
inflammator
y marker
IL-6 plays a
role in lung
diseases
CRS and
overproducti
on of
inflammator
y mediators
affects
clinical
severity
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Salvati, L., Occhipinti, M., Gori,
L., Ciani, L., Mazzoni, A., Maggi,
L., Capone, M., Parronchi, P.,
Liotta, F., Miele, V., Annuziato,
F., Lavorini, F., & Cosmi, L.
(2020). Pulmonary vascular
improvement in severe COVID19 patients treated with
tocilizumab. Immunology Letters,
228, 122-128.
doi.org/10.1016/j.imlet.2020.10.0
09
Science Direct

Evaluate the
imaging and
clinical response
one week after
TCZ treatment in
patients with
severe COVID19 requiring
intensive care

Population/
Sample/
Setting
Careggi
University
Hospital in
Florence, Italy

Study Design/
Variables/
Instruments
Retrospective,
observational,
single-center
study

33 patients: 20 in
TCZ group and
13 in control
group

Variables: age,
gender, oxygen
support,
outcome,
adverse events,
multiple lab
biomarkers,
CXR
Lung
parenchyma
scored by 2
independent
radiologists. 4point scale with
0 = no lung
involvement
and 4 = more
than 75%
involvement on
CXR
Data was
statistically
evaluated.

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

Mortality was
lower in TCZ
group than
control at 28d
(21% vs 46%)

TCZ may be
beneficial in
severely ill
patients by
decreasing
the
inflammatory
immune
response

Long-term
outcomes
need
evaluated

III

TCZ group:
significant
reduction in
FiO2 (p = 0.005)
and increase in
P:F ratio (p =
0.026) after 7d.
CRP, fibrinogen,
and ferritin
levels also
significantly
decreased.
No significant
reduction in
inflammatory
biomarkers were
seen in control
group after 7d.
Radiographic
score: lower in
TCZ group after
7d where control
group increased.

TCZ
promoted
earlier
pulmonary
vascular
recovery
Vascular
improvement
was less
dramatic than
lung
parenchymal
score,
indicating
that there is
still some
vascular risk
Selection bias

No steroids
used
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Tleyjeh, I.M., Kashour, Z.,
Damlaj, M., Riaz, M., Tlayjeh,
H., Altannir, M., Altannir, Y., AlTannir, M., Tleyjeh, R., Hassett,
L., & Kashour, T. (2020).
Efficacy and safety of
tocilizumab in COVID-19
patients: A living systematic
review and meta-analysis.
Clinical Microbiology and
Infection, 1-13.
doi.org/10.1016/j.cmi.2020.10.03
6
Pub Med

To execute a
systematic
review of the
literature
regarding the
efficacy and
toxicity of
tocilizumab in
patients with
COVID-19

Population/
Sample/
Setting
1325 patients
from the 5
chosen RCTs
and 10, 021 from
19 cohort studies
were evaluated.
Single-center
and multicenter
studies were
included
Multiple
countries were
included
Data is updated
every 3 months
(“living
systematic
review”).

Study Design/
Variables/
Instruments
Followed
Preferred
Reporting Items
for Systematic
Reviews
(PRISMA)
guidelines
9 databases
were reviewed.
Eligible studies
chosen by 8
reviewers in
groups of 2.
Discrepancies
resolved by 2
senior
reviewers.
The 5 RCTs
had low bias
per the ROB 2
scale, 18
cohorts at
moderate bias
risk
Heterogeneity
between studies
were
statistically
evaluated.
Data
statistically
analyzed

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

The RCTs did
not show that
TCZ had an
effect on
mortality

Sample size
for an RR of
0.73 on
mortality
would need a
TCZ group
size of 4506
(2253 in each
arm) patients,
so the RCT
sample size
of 772 in
TCZ group
and 553 in
control group
is too low for
determination
.

Possible
efficacy

I

For the cohort
studies, the
absolute risk
difference in
mortality when
compared to the
27.3% from the
International
Severe Acute
Respiratory and
Emerging
Infection
COVID-19
database was 11.5%
“Tocilizumab
reduces the risk
of mechanical
ventilation in
hospitalized
COVID-19
patients” (p.11).

Studies
varied greatly
and the
overall
quality of
evidence was
low due to
moderate risk
of bias
TCZ had low
risk for
infection or
adverse
events
Bias risk

Safety
includes
elevated
infection
risk
CRS
responsible
for the organ
damage in
severe
COVID-19
No steroids
mentioned
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Citation/
Search Engine

Purpose/
Objective

Xu, X., Han, M., Li, T., Sun, W.,
Wang, D., Fu, B., Zhou, Y.,
Zheng, X., Yang, Y., Li, X.,
Zhang, X., Pan, A., & Wei, H.
(2020). Effective treatment of
severe COVID-19 patients with
tocilizumab. Proceedings of the
National Academy of Sciences of
the United States of America,
117(20), 10970-10975
doi.org/10.1073/pnas.200561511
7
Pub Med

To assess the
efficacy of
tocilizumab on
severe COVID19 patients

Population/
Sample/
Setting
Anhui Provincial
Hospital and
Anhui Fuyang
Second People’s
Hospital in
China
21 patients: 17
severe by: RR ≥
30, O2 sat ≤ 93
on RA, P:F ratio
≤ 300. 4 critical
be needing ICU
admission for
MV, shock,
organ failure
All patients were
febrile and had
abnormal,
ground-glass
opacities via
chest CT on
presentation.

Study Design/
Variables/
Instruments
Retrospective,
observational
study
Evaluated via
clinical
manifestation,
CT imaging, lab
results

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

Temperatures
returned to
normal within a
day of TCZ
administration
and remained
stable

No control
group

Followed
temperatures
and
inflammator
y lab values

IV

75% had lower
oxygen
requirements by
Day 5.
CRP
significantly
decreased and
returned to
normal in 84.2%
of patients by
Day 5.
CT scans: vast
improvement in
90.5% of
patients.
IL-6 levels rose
in the short term
after TCZ

Small sample
size
“Tocilizumab
effectively
improves
clinical
symptoms
and represses
the
deterioration
of severe
COVID-19
patients.” (p.
10974).
No p values
were given
Potential bias

No adverse
events were
found postTCZ
Cytokine
storm seen
is similar to
SARS-CoV1 or MERSCoV
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Citation/
Search Engine

Purpose/
Objective

Zhao, J. & Tian, B-P. (2020)
Efficacy of tocilizumab treatment
in severely ill COVID-19
patients. Critical Care, 24(524),
1-4.
doi.org/10.1186/s13054-02003224-7
CINAHL

To examine the
efficacy of TCZ
treatment in
patients with
severe COVID19

Population/
Sample/
Setting
10 studies
included, 1675
severe COVID19 patients
One RCT and 9
retrospective
cohort studies
America, Europe
and India
600 TCZ group,
1000 control
group
TCZ was IV or
SQ and
doses/timing
varied
Varied steroid
use

Study Design/
Variables/
Instruments
Systematic
review and
meta-analysis
5 databases
searched and
two
independent
reviewers
selected eligible
studies
Discrepancies
evaluated by
group
discussion
Studies were
then statistically
compared

Results/
Main Findings

Implications/
Critiques

Comments/
Themes

Level of
Evidence

Significant
difference in
mortality
between TCZ
group and
control (p <
0.00001)

The reduction
in mortality
suggests that
TCZ is an
effective
treatment for
severe
COVID-19

Variable
steroid use

I

Significantly
high
heterogeneity
was observed
(p < 0.0001)
The low
quality of
studies and
variable
diagnostic
criteria for
severe
COVID-19
were limiting

Uncontrolle
d immune
activation
leads to
cytokine
storm
CRS appears
as
overproducti
on of
cytokines or
chemokines
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Table 3
Levels of Evidence

(Ackley, et al., 2008.)
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Table 4
Theme Matrix for Literature Review of tocilizumab use for severe COVID-19
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Appendix A Johns Hopkins Nursing Evidence Based Practice Model

PRACTICE QUESTION
Step 1: Recruit interprofessional team
Step 2: Define the problem
Step 3: Develop and refine the EBP question
Step 4: Identify stakeholders
Step 5: Determine responsibility for project leadership
Step 6: Schedule team meetings
EVIDENCE
Step 7: Conduct internal and external search for evidence
Step 8: Appraise the level and quality of each piece of evidence
Step 9: Summarize the individual evidence
Step 10: Synthesize overall strength and quality of evidence
Step 11: Develop recommendations for change based on evidence synthesis
• Strong, compelling evidence, consistent results
• Good evidence, consistent results
• Good evidence, conflicting results
• Insufficient or absent evidence
TRANSLATION
Step 12: Determine fit, feasibility, and appropriateness of recommendation(s) for translation path
Step 13: Create action plan
Step 14: Secure support and resources to implement action plan
Step 15: Implement action plan
Step 16: Evaluate outcomes
Step 17: Report outcomes to stakeholders
Step 18: Identify next steps
Step 19: Disseminate findings
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